Anti-eczema Mechanism of Action of Nigella sativa for Atopic Dermatitis: Computer-aided Prediction and Pathway Analysis Based on Protein-chemical Interaction Networks by Widyaswari, Meidyta Sinantryana et al.
BIOMOLECULAR AND HEALTH SCIENCE JOURNAL 2019 OCTOBER, VOL 02 (02)
ORIGINAL ARTICLE
68
Anti-eczema Mechanism of Action of Nigella sativa 
for Atopic Dermatitis: Computer-aided Prediction 
and Pathway Analysis Based on Protein-chemical 
Interaction Networks
Meidyta Sinantryana Widyaswari1, Iis Noventi2, Herdiantri Sufriyana3,4*
1Department of of Dermatology and Venereology, College of Medicine, University of Nahdlatul Ulama Surabaya, Indonesia
2Department of Medical-Surgical Nursing, College of Nursing and Midwifery, University of Nahdlatul Ulama Surabaya, 
Indonesia
3Department of Medical Physiology, College of Medicine, University of Nahdlatul Ulama Surabaya, Surabaya, Indonesia
4Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taipei Medical University, 
Taipei, Taiwan
A R T I C L E  I N F O A B S T R A C T
Article history: 
Received 26 August 2019
Received in revised form 14 
October 2019
Accepted 21 October 2019
Keywords:
Nigella sativa,
atopic dermatitis,
protein-chemical interaction 
networks, 
PASS.
Introduction: Black cumin (Nigella sativa) is widely used to treat various diseases. It is also 
believed to relief skin conditions accompanied by itching symptom, such as atopic dermatitis 
(AD) or eczema. However, the anti-eczema mechanism of action is still unclear. The aims of this 
syudy was to  identify anti-eczema mechanism of action of N. sativa for AD using computer aided 
prediction and pathway analysis based on protein-chemical networks. 
Methods: We utilized dataset consisting chemical compounds of N. sativa from KNApSAcK. It 
is a comprehensive species-metabolite relationship database. Using canonical SMILES strings that 
encode molecular structures of each compound, we predicted the probabilities of activity (Pa) for 
anti-eczema effect based on PASS algorithms. The compounds with Pa >0.7 were included for 
pathway analysis based on protein-chemical interaction networks in STITCH database. We selected 
interactomes built by experimental data, gene co-expression, closest gene position, fusion, co-
occurence, computational prediction, and other secondary data. 
Results: Thirty-five active compounds of N. sativa have been utilized and 19 of them have potential 
anti-eczema effects. Oleic acid and lauric acid were predicted with Pa-value of 0.947 and 0.920 
for anti-eczema effect, respectively. However, only lauric acid was confirmed having a plausible 
mechanism of action via LY96-TLR4- PIK3R1 pathway for lipopolysaccharide receptor activity 
(false discovery rate [FDR] = 0.0243) and low-density lipoprotein particle receptor binding (FDR 
= 0.0118). 
Conclusion: Lauric acid in N. sativa has potential antieczema effect to prevent relaps in AD patients 
by controlling opportunistic bacterial infection that aggravates itching symptom in this condition.
© 2019 Biomolecular and Health Science Journal. All rights reserved
Introduction
Atopic dermatitis (AD), or eczema, is a chronic, 
recurrent skin inflammation accompanied by severe 
itching and dry skin on certain area of skin predilection. 
It commonly occurs at early childhood and relapse 
at adulthood. Ten percent of the cases may last up to 
adolescence or adulthood. Prevalence of AD varied among 
countries, which have increased worldwide, especially in 
industrialized countries. The prevalence was 10-20% in 
children, while it was 1-3% in adults. This multifactorial 
disease has unclear etiopathogenesis, but it generally 
involves complex interactions of skin barrier function, 
immune system disorders, genetics, and other factors, 
including environment, diet, infection, and stress.1
Mismanagement of AD often occurs because of its 
similarity to other chronic skin diseases. This disease 
commonly occurs in primary care.2 As a chronic skin 
inflammatory disease, a primary choice of long-term 
treatment is topical drugs, particularly those with a steroid 
compound. Its use may not be acceptable for the patients 
who believe this as a chemical substance which is harmful 
for long-term use. In several cultures, particularly in 
Indonesia, it is widely accepted that medicinal plants are 
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safe for long-term use. Black cumin is one of the medicinal 
plants. It may improve quality of life of the patients and 
reduce severity of the disease.3
Black cumin (Nigella sativa) is a plant that grows up 
to 20-90 cm in height, finely-separated leaves, and flowers 
with multiple colors. These are white, yellow, pink, pale 
blue and pale purple. Each flower consists 5-10 crowns. 
The large fruits contain several seeds. This plant is one of 
the most common medicinal plants that were investigated. 
It is because of its wide spectrum of applications in 
traditional medicine from many countries worldwide. The 
seeds are commonly used to treat various diseases. Most 
of the therapeutic effects are contributed by thymoquinone 
which is the main active ingredient in the seed’s oil. 
Several studies have demonstrated that this plant could be 
used as an antidiabetic, anticancer, immunomodulator, pain 
reliever, antimicrobial, antioxidant, hepatoprotector, and 
others.4 However, an active substance of N. sativa, which 
has antieczema effect, is still unclear.
To perform a preclinical research efficiently, we need to 
conduct preliminary study identifying the active substance 
and its mechanism action. We utilized dataset of active 
compounds from a database of plants. A classification 
algorithm can be used to predict the antieczema effect 
based on a structure-activity relationship models derive 
from other chemical substances. The mechanism of action 
can be predicted by protein-chemical interactomes using 
over representation analysis. This study aims to identify 
active compounds of N. sativa, which have antieczema 
effect, and its mechanism of action for AD using computer-
aided prediction and pathway analysis based on protein-
chemical interaction networks.
Methods
Study design and data source
We applied a descriptive exploratory study design. This 
study utilized dataset from KNApSAcK database (http://
kanaya.naist.jp/KNApSAcK/) at April 13th, 2018. Active 
compounds’ data of N. sativa were retrieved without 
considering which parts of plant had been taken to identify 
these compounds. We only selected those which have 
available data in protein-chemical interaction database. In 
addition, these compounds should have canonical structure 
information as inferred from simplified molecular-input 
line-entry system (SMILES) in PubChem database (https://
pubchem.ncbi.nlm.nih.gov/).
Prediction of antieczema effect
Selected compounds were predicted for their effects 
by quantitative structure-activity relationship (QSAR) 
modeling. We used prediction of activity spectra for 
substances (PASS) web application (http://pharmaexpert.
ru/PASSonline) to apply its classification algorithm based 
on the QSAR model. This web application classified the 
selected compounds into several classification systems. 
We only looked for those that were classified by its 
pharmacological effect, particularly with probability of 
activity (Pa) >0.7 for antieczema.
Pathway analysis to identify antieczema mechanism of 
action
To identify mechanisms of action for these compounds, 
we used search tool for interacting chemicals (STITCH) 
platform (http://stitch.embl.de). By over representation 
analysis (ORA), this platform annotated the compounds 
with existing protein-chemical interactomes in STITCH 
database. We configured ORA to analyze the compounds 
based on experimental data, gene co-expression, closest 
gene position, gene fusion, co-occurence, computational 
prediction, and other secondary data. We configured 
interaction confidence to be 0.400 for the minimum value. 
Other parameter configuration was maximum 10 interactors 
for each layer up to the second interaction layer.
The platform also retrieved information gene ontology 
(GO) database for functional enrichment analysis. The 
information consisted of biological process, molecular 
function, and cellular component, which are involved in 
the interactomes. Individual GO information was used to 
identify which one was related to antieczema based on 
previous studies.
We also determined a gene set consisted of genes which 
involved in the antieczema interactomes. Pathway analysis 
was conducted by including this gene set with that related 
to AD based on previous studies. Eventually, this analysis 
identified antieczema mechanism of action in silico.
Results
Retrieved active compounds of Nigella sativa
Active compounds N. sativa were retrieved from 
KNApSAcK database (Table 1). Thirty-five active 
compounds were obtained. Although this database did not 
provide which parts of the plant that the compounds were 
identified, previous studies showed that thymoquinone was 
mostly identified in seed’s oil.4, 5
The active compounds with antieczema effect
The active compounds have been selected based on the 
criteria (Table 2). Nineteen of 35 active compounds have 
predicted antieczema effect with Pa-value of >0.7 and 
available in protein-chemical interactomes of STITCH 
database. Six compounds on STITCH database were 
identical with those in PubChem database. Canonical 
SMILES codes of these compounds from PubChem were 
used as features to predict the antieczema effect. Oleic acid 
was a compound of N. sativa that had highest biological 
activity is (Pa-value=0.947). However, pathway analysis 
showed that lauric acid had relevant antieczema effect with 
Pa-value which was closest to that of oleic acid (Pa=0.920).
Predicted antieczema mechanism of action
Pathway analysis was conducted to identify antieczema 
mechanism of action (Figure 1). Several interactomes 
over-represented oleic acid and lauric acid. The 
interactomes included genes/transcripts/proteins coded by 
the gene name. These were FAAH, PMP2, RBP1, APOE, 
APOB, LDLR, PCSK9, GLTP, ALB, UBC, MTRNR2L2, 
LTB4R2, GPR68, LY96, TLR4 and FCGRT. In addition, 
the interactomes also included other chemical substances. 
Therefore, two of active compounds contained by N. 
sativa were active substances that had been known having 
interactions with several proteins
To confirm which interactomes were related to the 
anti-eczema mechanism of action, functional enrichment 
analysis was carried out (Table 3). Majority of the GO 
information were related to cholesterol metabolism and 
interactions with lipopolysaccharides (LPS). Interaction 
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with LPS was considered having a role in pathophysiology 
of AD because of LY96 and TLR4. Increasing transepidermal 
water loss, allergic sensitization, and thickness of epidermis 
were demonstrated on AD lesion of a mice model with TLR4 
deficiency that had been exposed to allergen derived from 
Aspergillus fumigatus for 3 weeks.7 Oleic acid may also play a 
role in determining occurrence of AD via cholesterol metabolic 
pathway. Hyperlipidemia was found as comorbidity (10.35%) 
in 30,354 patients with AD compared to those without AD.8
A gene set related to AD were determined based on a 
previous study.9 This consisted of LOR, KRT17, SPRR2D, 
SPRR1A, SPRR1B, IVL, CCR7, CCL19, PIK3R1, and 
STAT1. These gene names along with LY96, TLR4, and lauric 
acid were analyzed by STITCH platform (Figure 2). Lauric 
acid, LY96, and TLR4 were over-represented by interactomes 
that were annotated as LPS detection for the biological 
process, LPS receptor activity for the molecular function, and 
LPS receptor complex for the cellular components. This was 
considered having a greater role in antieczema mechanism of 
action compared to other GO information related to cholesterol 
metabolism. The LY96 and TLR4 had interactions with 
MYD88 that connected them to AD via PIK3R1. The score 
was 0.576 for interaction of MYD88 and the gene set.
Table 1. Active compounds of Nigella sativa retrieved from KNApSAcK database. 
Active compounds Molecular formula Molecular weight (kD)
Thymol C10H14O 150.1044651
Carvacrol C10H14O 150.1044651
alpha-Thujene C10H16 136.1252005
alpha-Pinene C10H16 136.1252005
beta-Pinene C10H16 136.1252005
Myrcene C10H16 136.1252005
Lauric acid C12H24O2 200.17763
Oleic acid C18H34O2 282.2558803
Anisaldehyde C8H8O2 136.0524295
Apiol C12H14O4 222.0892089
Estragol C10H12O 148.088815
Myristicin C11H12O3 192.0786443
(+)-R-Citronellol C10H20O 156.1514153
p-Cymene C10H14 134.1095505
(+)-Fenchone C10H16O 152.1201151
alpha-Phellandrene C10H16 136.1252005
gamma-Terpinene C10H16 136.1252005
Longifolene C15H24 204.1878008
(Z,Z,Z)-Octadeca-9,12,15-trienoic acid C18H30O2 278.2245802
Thymoquinone C10H12O2 164.0837296
Kaempferol 3-glucosyl-(1->2)-galactosyl-(1->2)-
glucoside C33H40O21 772.2062083
Quercetin 3-glucosyl-(1->2)-galactosyl-(1->2)-glucoside C33H40O22 788.201123
Quercetin 3-(6''''-feruloylglucosyl)-(1->2)-
galactosyl-(1->2)-glucoside
C43H48O25 964.2484671
Fuzitine C20H24NO4 342.1705333
Nigellicine C13H14N2O3 246.1004423
Nigellidine C18H18N2O2 294.1368278
Nigellimine C12H13NO2 203.0946287
4-Terpineol C10H18O 154.1357652
4(10)-Thujene C10H16 136.1252005
Nigeglanine C12H14N2O 202.1106131
Nonane C9H20 128.1565006
Carvone C10H14O2 166.0993797
alpha-Longipinene C15H24 204.1878008
Dihydrocarvone C10H16O 152.1201151
Nigellidine 4-O-sulfite C18H18N2O5S 374.0936424
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Table 2. Active compounds of Nigella sativa with antieczema affect.*
Active compounds Pa-value**
Oleic acid 0.947
Lauric acid 0.920
beta-Pinene (pinene***) 0.902
Nonane 0.895
Dihydrocarvone (trans-dihydrocarvone***) 0.889
p-Cymene 0.884
Estragol (estragole***) 0.881
Longifolene 0.878
alpha-Thujene (thujene***) 0.866
gamma-Terpinene 0.854
4-Terpineol (terpinen-4-ol atau 4-carvomenthenol***) 0.838
Myrcene 0.836
Carvacrol 0.811
Myristicin 0.795
Apiol (apiole***) 0.794
Thymol 0.788
alpha-Phellandrene 0.772
Thymoquinone 0.762
Carvone 0.737
* Available in STITCH database, predicted as antieczema, and Pa-value >0.7
** Probability of activity
*** Synonyms in STITCH and PubChem
Figure 1. Interactomes of protein and chemical substances including active compounds of Nigella sativa. Color of lines 
denoted specific types of action, which were activation (green), binding (blue), phenotype (cyan), reaction (black), in-
hibition (red), catalysis (purple), posttranslational modification (pink), and transcriptional regulation (yellow). End 
shape of arrow denoted action effects, which were positive (triangle), negative (vertical line), and unspecified (round). 
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Table 3. Gene ontology (GO) from interactomes involving oleic acid and lauric acid based on functional enrichment analysis.
Gene ontology Pathway identifier Pathway description Count in gene set False discovery rate
Biological 
process
GO:0042159 Lipoprotein catabolic process 3 0.00491
GO:0032805
Positive regulation of low density 
lipoprotein particle receptor cata-
bolic process
2 0.0176
GO:0042632 Cholesterol homeostasis 4 0.0176
GO:0001523 Retinoid metabolic process 4 0.0217
GO:0034381 Plasma lipoprotein particle clearance 3 0.0217
GO:0032497 Detection of lipopolysaccharide 2 0.0295
GO:0007603 Phototransduction, visible light 4 0.0321
GO:0008203 Cholesterol metabolic process 4 0.041
GO:0006869 Lipid transport 5 0.0462
GO:0008202 Steroid metabolic process 5 0.0462
Molecular 
function
GO:0050750
Low-density lipoprotein particle re-
ceptor binding 3 0.0118
GO:0071813 Lipoprotein particle binding 3 0.013
GO:0070326
Very-low-density lipoprotein particle 
receptor binding 2 0.0174
GO:0001875 Lipopolysaccharide receptor activity 2 0.242
Cellular
component
GO:0034362 Low-density lipoprotein particle 3 0.0029
GO:1990666 PCSKg-LDLR complex 2 0.0029
GO:0046696 Lipopolysaccharide receptor complex 2 0.00579
GO:0034363 Intermediate-density lipoprotein par-ticle 2 0.013
Figure 2 Interactomes of protein and chemical substances including ten gene names involved in AD along with LY96, TLR4 
and lauric acid. Color of lines denoted specific types of action, which were activation (green), binding (blue), phenotype 
(cyan), reaction (black), inhibition (red), catalysis (purple), posttranslational modification (pink), transcriptional regulation 
(yellow), and unspecified (grey). End shape of arrow denoted action effects, which were positive (triangle), negative (vertical 
line), and unspecified (round).
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Discussion
Lauric acid was predicted having antieczema effect 
for AD with a plausible mechanism of action. It was 
indicated by interaction of lauric acid with LY96 and 
TLR4. Concurrently, both gene names were connected 
to PIK3R1 which was a part of interactomes involving 
proteins related to AD. The GO information of these 
interactomes indicated that LPS was involved in 
antieczema mechanism of action for lauric acid as an 
active compound of N. sativa.
Topical administration of N. sativa seed’s oil showed 
antieczema effect in patients who applied this oil twice 
a day for 28 days. The nineteen patients demonstrated 
lower hand eczema severity index (HECSI) compared to 
those eighteen patients given eucerin as negative controls 
(P=0.003). Likewise, the dermatology life quality index 
(DLQI) was also lower (P<0.0001). There was no 
difference with patients given betamethasone as positive 
controls for HECSI (P=0.99) or DLQI (P=0.38).4
Conversely, there was no difference in efficacy for 
twenty patients who applied the formulation of N. sativa 
oil on one hand and placebo on the other hand. The 
efficacy was no difference in terms of severity, pruritis, 
transepidermal water loss, and skin hydration.6 However, 
this might occur due to difference in composition of active 
compounds. It might also occur because of different 
composition of inactive compounds in the formulation.
The LY96 protein that binds to TLR4 as its receptor 
was connected to interactomes related to AD via MYD88. 
The interaction score of MYD88 with the interactomes 
was moderately significance. Clinical manifestations 
of patients with MYD88 gene deficiency indicated 
inflammation of the skin. The MYD88 protein is an 
adapter protein receiving signals from extracellular to 
intracellular proteins, particularly by binding CBLB in 
this study, a negative regulator of T-cell activation.
In turn, the CBLB protein was indicated by the 
pathway as a catalyzer for PIK3R1 as the downstream 
protein related to AD, which encodes a regulatory subunit 
of phosphoinositide 3-kinase.12 The role of PIK3R1 in AD 
were investigated by few studies,13, 14 indicating a potential 
novel target for AD treatment. This protein extensively 
interacted with other proteins, such as STAT1 that acts 
as a transcription factor involved in chemokine signaling 
pathway, including that in peripheral mononuclear cells of 
AD patients.15 
Another protein, which is KRT17, was also connected 
with the extensive interactions involving PIK3R1. The 
gene of KRT17 was upregulated along with IVL in canine 
AD.16 The IVL expression demonstrated reduction of 
genes expression for proteins that maintain epidermal 
barrier, which were EGFR, e-cadherin, occludin, 
envoplakin, and periplakin.17, 18
The inflammation of skin involving MYD88 was also 
due to infection by two opportunistic bacteria which were 
Staphilococcus aureus and Pseudomonas aeruginosa.10 
Atopic dermatitis is a common skin disease involving 
microbial infection. This was shown by dominance of S. 
aureus, including those that were resistant to methicillin, 
like many Streptococcus sp. and P. aeruginosa.11 The 
antieczema effect may occur by increasing activity 
of these proteins to control opportunistic bacterial 
population by detection of LPS and activation of innate 
immunity. Inflammation allegedly persists for controlling 
opportunistic bacteria; thus, the severity of AD is reduced. 
Conversely, if opportunistic bacteria are out of control, 
more severe inflammatory response may occur. Eventually, 
this may prevent relapse occurrence in AD patients.
Our study presents prediction of pharmacological 
effect and pathway analysis that showed lauric acid 
contains in N. sativa has a potential role as antieczema 
to relieve inflammation in AD. Computer-aided prediction 
and the pathway analysis may save time for ligand-based 
drug discovery. This in silico analysis can be a starting 
point to conduct in vitro and in vivo testing.
However, computational prediction may possess a 
risk of bias. This depends on available datasets that were 
utilized to train the prediction model. Features of the 
chemical structure in active compounds of N. sativa may 
be unobserved in the datasets. This may increase false 
discovery rate of the prediction model. 
Conclusion
Lauric acid, via LY96-TLR4-PIK3R1 pathway, was found 
to be potential target to prevent relapse in AD patients. 
Topical administration of N. sativa seed’s oil may be more 
acceptable in several cultures in Indonesia. However, 
prevention of relapse still requires further investigation 
to prove the efficacy to prevent AD relapse as well as 
toxicity testing for chronic administration. 
Further computational investigation will be an analysis of 
potential binding site for lauric acid to the corresponding 
proteins. Affinity of the active compounds will determine 
its feasibility for wet laboratory testing. This study may 
help to estimate proper dosage for preclinical study.
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